Earnings ·
Reports Q3 net product revenue of $92.1 million, secures $750M term loan
RYTMRhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals reported third-quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, a 29% increase from the prior quarter and up from $51.3 million in Q3 2025. The company also announced it secured a five-year term loan facility providing access to up to $750 million, with an initial draw of $250 million. Additionally, Rhythm amended its licensing agreement for bivamelagon, reducing the royalty rate on its MC4R portfolio to 1% in exchange for $350 million in fixed payments over four years. The company reported a net loss attributable to common stockholders of $42.4 million, or $0.61 per share, compared to a $54.3 million loss in the prior year period. Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on treating rare neuroendocrine diseases.